Synthetic peptide aMPC16-CA50 induces immunogenic cell death, boosts checkpoint therapy in mice
This digest was compiled by AI from multiple sources — links to the originals are below.
Researchers have designed a synthetic pH-responsive membranolytic peptide, aMPC16-CA50, that induces immunogenic membranolytic cell death in tumor cells. The peptide triggers a time-lagged rupture from lysosomes to plasma membranes, activating an inflammatory program that enhances antigen presentation and T cell activation. Systemic administration of aMPC16-CA50 robustly enhanced immune checkpoint blockade therapy in mice and was well-tolerated.
Membrane Ripping Mechanism
The peptide aMPC16-CA50 is engineered with hierarchical responsiveness to the declining pH of the tumor microenvironment and lysosomal lumen. It accumulates on lysosomal membranes before migrating to the plasma membrane, causing sequential rupture. This spatiotemporal control of membrane disruption programs a distinct immunogenic cell death mode termed mLCD.
Immune System Engagement
In tumor cells, aMPC16-CA50 turned on a transcriptional inflammatory program that strengthened antigen presentation on MHC class I molecules in dendritic cells. This cascade led to potent T cell priming. The peptide's lytic kinetics were critical for maximizing the immunogenicity of dying cells.
Therapeutic Synergy
In mouse tumor models, aMPC16-CA50 combined with immune checkpoint blockade outperformed either treatment alone. Tumors shrank markedly, with durable responses in a subset. Systemic administration showed no significant toxicity at effective doses.
What's Next
The discovery team is expected to launch IND-enabling studies for aMPC16-CA50 within the next year. Whether the strong antitumor immunity and safety profile will hold in human trials remains uncertain, given the complexity of translating peptide-based lytic agents.
1 source
Synthetic peptide aMPC16-CA50 induces immunogenic cell death, boosts checkpoint therapy in mice
